View More View Less
  • 1 Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Miskolc, Csabai kapu 9–11., 3529
  • 2 Pannon Egyetem, Veszprém
  • 3 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen
Open access

Absztrakt:

A krónikus obstruktív tüdőbetegség (COPD) világszerte előkelő helyet foglal el a morbiditási és mortalitási statisztikákban. A COPD megelőzhető és kezelhető betegség, kialakulásáért döntően a dohányzás tehető felelőssé. A prevenció kulcsfontosságú, de korlátozottan kivitelezhető, így a rizikó meghatározása és a korai noninvazív diagnosztika révén lehetne tovább csökkenteni a COPD miatti halálozást. A fejlődő diagnosztikus technikák ellenére az optimális szűrővizsgálat felfedezése még várat magára. Kellően szenzitív és specifikus biomarkerek felfedezése megfelelő eszközt adhat a klinikus kezébe a betegség korai diagnosztizálásához, a differenciáldiagnosztikához, a fenotipizáláshoz és a prognózis becsléséhez. Közleményünkben a COPD vonatkozásában a közelmúltban felfedezett potenciális fehérje és glikán biomarkereket foglaljuk össze. Orv Hetil. 2020; 161(4): 123–128.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease among adults – United States, 2011. Morb Mortal Wkly Rep. 2012; 61: 938–943.

  • 2

    Böszörményi NGy. COPD. [COPD.] Korányi Bull. 2019; 1: 24–31. [Hungarian]

  • 3

    Braido F, Bagnasco D, Scichilone N, et al. Biomarkers in obstructive respiratory diseases: an update. Panminerva Med. 2012; 54: 119–127.

  • 4

    Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the ‘stroke of the lungs’? Int J Chron Obstruct Pulmon Dis. 2016; 11: 1579–1586.

  • 5

    Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7: 95–99.

  • 6

    Csánky E, Takács L. The role of biomarkers in COPD pathogenesis. [A biomarkerek szerepe a COPD patogenezisében.] Tüdőgyógyászat 2007; 12: 3–11. [Hungarian]

  • 7

    Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015; 148: 971–985.

  • 8

    Csánky E, Rühl R, Scholtz B, et al. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis 2009; 30: 1228–1234.

  • 9

    Poliska S, Csánky E, Szántó A, et al. Chronic obstructive pulmonary disease-specific gene expression signatures of alveolar macrophages as well as peripheral blood monocytes overlap and correlate with lung function. Respiration 2011; 81: 499–510.

  • 10

    Csánky E, Olivova P, Takács L. Monoclonal antibody proteomics: discovery and pre-validation of COPD biomarkers in a single step. Electrophoresis 2007; 28: 4401–4406.

  • 11

    Indovina P, Marcelli E, Maranta P, et al. Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011; 2011: 726869.

  • 12

    Zamay TN, Zamay GS, Kolovskaya OS, et al. Current and prospective protein biomarkers of lung cancer. Cancers 2017; 9: 155.

  • 13

    Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014; 18: 273–284.

  • 14

    Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008; 31: 869–873.

  • 15

    Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68: 670–676.

  • 16

    Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. J Chronic Obstr Pulm Dis. 2015; 2: 23–34.

  • 17

    Cheng DT, Kim DK, Cockayne DA, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 948–957.

  • 18

    Park HY, Churg A, Wright JL, et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 1413–1419.

  • 19

    Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 183: 1187–1192.

  • 20

    Lai T, Wu D, Chen M, et al. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling. Respir Res. 2016; 17: 31.

  • 21

    Minas M, Mystridou P, Georgoulias P, et al. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD 2013; 10: 28–34.

  • 22

    Johansson SL, Roberts NB, Schlosser A, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir Med. 2014; 108: 1336–1344.

  • 23

    Ju CR, Liu W, Chen RC. Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis Markers 2012; 32: 281–287.

  • 24

    Xia J, Zhao J, Shang J, et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015; 308: L619–L627.

  • 25

    Chen YW, Leung JM, Sin DD. A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS ONE 2016; 11: e0158843.

  • 26

    Jaswal S, Saini V, Kaur J, et al. Evaluation of circulating protein biomarkers of inflammation in COPD. J Med Sci Clin Res. 2017; 05: 20202–20206.

  • 27

    Silva DR, Gazzana MB, Knorst MM. C-reactive protein levels in stable COPD patients: a case-control study. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1719–1725.

  • 28

    Kurt OK, Tosun M, Kurt EB, et al. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation 2015; 38: 89–93.

  • 29

    El-Deek SE, Makhlouf HA, Saleem TH, et al. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med Princ Pract. 2013; 22: 469–474.

  • 30

    Lee KY, Chuang HC, Chen TT, et al. Proteoglycan 4 is a diagnostic biomarker for COPD. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1999–2007.

  • 31

    Zhang M, Zhang J, Zhang Q, et al. D-dimer as a potential biomarker for the progression of COPD. Clin Chim Acta 2016; 455: 55–59.

  • 32

    Merali S, Barrero CA, Bowler RP, et al. Analysis of the plasma proteome in COPD: novel low abundance proteins reflect the severity of lung remodeling. COPD 2014; 11: 177–189.

  • 33

    Kovács Z, Simon Á, Szabó Z, et al. Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma. Electrophoresis 2017; 38: 2115–2123.

  • 34

    Gao C, Taniguchi N. Glycans and chronic obstructive pulmonary disease (COPD). In: Suzuki T, Ohtsubo K, Taniguchi N. (eds.) Sugar chains. Springer Japan, Tokyo, 2015, pp. 259–266.

  • 35

    Angata T, Fujinawa R, Kurimoto A, et al. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann N Y Acad Sci. 2012; 1253: 159–169.

  • 36

    Ito E, Oka R, Ishii T, et al. Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease. J Proteomics 2015; 127: 386–394.

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

Mendeley citation style is available HERE.

 

MANUSCRIPT SUBMISSION

  • Impact Factor (2018): 0.564
  • Medicine (miscellaneous) SJR Quartile Score (2018): Q3
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu